Mark Kamps

Title: Mark Kamps: Innovator in Hematopoietic Cell Research

Introduction

Mark Kamps is a notable inventor based in Carlsbad, California. He has made significant contributions to the field of immunology and hematopoietic cell research. With a total of 2 patents, his work focuses on innovative methods for generating immune cells and studying their responses.

Latest Patents

Kamps' latest patents include a method for the derivation of unlimited quantities of neutrophils or monocyte/dendritic cells. This invention discloses a technique to generate unlimited numbers of macrophage/dendritic cells or neutrophils from mice, utilizing conditional Hox oncoproteins. The invention also establishes a system to investigate immune responses to microorganisms or diseases involving chronic inflammation. Another significant patent is a genetic construct comprising the coding sequence for a hormone-dependent E2a-Pbx1 protein. This construct is used to generate hematopoietic cell lines that are arrested in differentiation upon exposure to the appropriate hormone. Upon removal of the hormone, these cells undergo normal, synchronous differentiation, providing a system for studying normal differentiation and the mechanisms of leukemia.

Career Highlights

Mark Kamps is affiliated with the University of California, where he continues to advance research in his field. His work has implications for understanding immune responses and developing treatments for diseases related to chronic inflammation and leukemia.

Collaborations

Kamps collaborates with David B Sykes, contributing to the advancement of research in hematopoietic cell biology.

Conclusion

Mark Kamps is a prominent inventor whose work in hematopoietic cell research has the potential to impact the understanding and treatment of various diseases. His innovative patents reflect his commitment to advancing scientific knowledge in immunology.